Search
San Diego based Origami Therapeutics is developing next-generation protein degraders and correctors for CNS conditions - the lead program is focused on Huntington's disease
Founder & CEO Beth Hoffman describes how Origami's platform is different than other degrades like PROTACs, and how it specifically is designed to clear the mutant huntingtin protein. Plus, details on a global collaboration announced earlier this year with Ipsen. Coverage brought to you by
Jun 26
.png){kind=logo}